Response to "A financial perspective on the topical treatment of onychomycosis".
University of Alabama at Birmingham. Electronic address: beelewski@aol.com.
Boni E
BE
Elewski
D000287:Administration, Topical; D000935:Antifungal Agents / Q000008:administration & dosage / Q000191:economics; D001896:Boron Compounds / Q000191:economics* / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D005533:Foot Dermatoses / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008297:Male; D014009:Onychomycosis / Q000175:diagnosis / Q000188:drug therapy*; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D014230:Triazoles / Q000191:economics* / Q000627:therapeutic use
D000935:Antifungal Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D014230:Triazoles; C431707:efinaconazole; C512998:tavaborole